HELP LDL Apheresis Reduces Plasma Pentraxin 3 in Familial Hypercholesterolemia

HELP LDL Apheresis Reduces Plasma Pentraxin 3 in Familial Hypercholesterolemia

BACKGROUND Pentraxin 3 (PTX3), a key component of the humoral arm of innate immunity, is secreted by vascular cells in response to injury, possibly aiming at tuning arterial activation associated with vascular damage. Severe hypercholesterolemia as in familial hypercholesterolemia (FH) promotes vascular inflammation and atherosclerosis; low-density lipoprotein (LDL) apheresis is currently the t...

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia

Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia.

BACKGROUND Patients with familial hypercholesterolemia (FH) are characterized by elevated atherogenic lipoprotein particles, predominantly low-density lipoprotein cholesterol (LDL-C), which is associated with accelerated atherogenesis and increased cardiovascular risk. OBJECTIVES This study used (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) to investigate whether arteria...

Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia.

Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is, however, unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates, conversion rates, and fractional catabolic rates (FCR). We studied the long-term effect of regular apheresis therapy on metabolic parameters o...

LDL apheresis in a woman with severe heterozygous familial hypercholesterolemia. Late, but not too late

Familial hypercholesterolemia (FH) is an under-recognized and undertreated common lipid metabolism disorder [1, 2]. Early and intensive treatment reduces consequent mortality from coronary heart disease [3, 4]. A promising tool for retarding or arresting the atherosclerotic process in hypercholesterolemic patients refractory to maximally tolerated pharmacotherapy is LDL apheresis [5, 6]. We pre...